BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ventaira Pharmaceuticals Announces Acquisition of Assets by Battelle


10/30/2007 7:38:28 AM

COLUMBUS, Ohio, Oct. 29 /PRNewswire/ -- Ventaira Pharmaceuticals announced today that Battelle, a science and technology development leader, will acquire Ventaira's assets and assist Ventaira in closing its operations. Financial terms of the acquisition were not disclosed.

"We will be working with Battelle to transition our assets. In addition, we will work closely with Battelle to explore employment opportunities for our employees," said Leslie Williams, President and CEO of Ventaira Pharmaceuticals. "I would like to thank all of our investors and employees for their dedication to Ventaira and our technology."

Ventaira's clinical development program and device development work are discontinued effective today, Oct. 29, 2007. Operations at Ventaira are expected to close by Dec. 31, 2007.

About Ventaira

Ventaira is a specialty pharmaceutical company based in Columbus, Ohio that develops a proprietary pulmonary drug delivery technology, Mystic(TM) (Electrohydrodynamic-EHD), and formulation capabilities to deliver drugs more efficiently to and through the lung. EHD is an electronic nebulization process in which an electrical field is applied to a conductive liquid leading to the formation of a soft mist droplet aerosol. Ventaira was spun out from Battelle in 2000.

About Battelle

Battelle provides solutions to some of the world's most important challenges through its three global businesses: National Security, Energy Technology, and Health and Life Sciences. Battelle is the world's largest independent research and development organization with technology contributions that find their way into hundreds of commercial products each year. Conducting $3.8 billion in global R&D annually, Battelle oversees 20,000 employees in more than 120 locations worldwide, including five national laboratories Battelle manages or co-manages for the U.S. Department of Energy.

Headquartered in Columbus, Ohio, and established in 1929 as a non-profit charitable trust, Battelle focuses on societal and economic impact and actively supports and promotes science and math education.

CONTACT: Leslie Williams, President and CEO of Ventaira Pharmaceuticals,
+1-614-340-2338



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES